Chronic Obstructive Pulmonary Disease
Chronic inflammatory lung disease that causes irreversible obstructed airflow, primarily from smoking.
Emergency Management: Acute Exacerbation of COPD (AECOPD) presenting with severe dyspnea, confusion, and acidosis (pH < 7.35) requiring Non-Invasive Positive Pressure Ventilation (BiPAP), systemic steroids, and antibiotics.
A common, preventable, and treatable chronic lung disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities, mostly caused by significant exposure to noxious particles or gases.
Detailed Overview
COPD encompasses two main phenotypes: emphysema (alveolar destruction) and chronic bronchitis (small airway inflammation with mucus hypersecretion). The hallmark is irreversible airflow obstruction. Patients suffer from progressive dyspnea and exacerbations, predominantly triggered by viral or bacterial infections. Smoking cessation is the only intervention that definitively alters the natural disease course.
Epidemiology & Demographics
Third leading cause of death worldwide. Global prevalence is ~10-12% in adults over 40. Equal prevalence in men and women in developed nations.
Etiological Mechanism
Long-term inhalation of noxious particles, predominantly cigarette smoke, or genetic deficiency of alpha-1 antitrypsin.
Primary Causes
Cigarette smoking (80-90% of cases), indoor biomass fuel exposure (developing nations).
Noxious particles trigger macrophage and neutrophil infiltration in the lungs. In chronic bronchitis, neutrophils release elastase and mucin-stimulating cytokines, causing goblet cell hyperplasia and mucus plugging of bronchioles. In emphysema, the imbalance of proteases (overactive) and antiproteases (depleted) destroys the alveolar septa. This reduces elastic recoil, causing small airways to collapse during exhalation, trapping air (hyperinflation) and reducing the surface area for gas exchange.
Diagnostic Criteria & Guidelines
Spirometry is required for diagnosis: Post-bronchodilator FEV1/FVC ratio < 0.70 confirms persistent airflow limitation.
Smoking cessation is paramount. LAMA (Long-Acting Muscarinic Antagonist e.g., Tiotropium 18 mcg inhaled daily). If symptoms persist or exacerbations occur, combine with LABA (Long-Acting Beta Agonist e.g., Formoterol).
Second-Line & Adjunctive Therapy
Triple therapy (LAMA + LABA + Inhaled Corticosteroid like Fluticasone) for frequent exacerbators with blood eosinophils >300 cells/uL. Roflumilast (PDE4 inhibitor) for severe chronic bronchitis.
Surgical & Procedural Management
Lung Volume Reduction Surgery (LVRS) or endobronchial valves for severe upper-lobe predominant emphysema. Lung transplantation for refractory end-stage disease.
Patient Counseling & Advice
Inhaler technique is critical; demonstrate and ask for teach-back. Emphasize that smoking cessation stops the accelerated lung function decline.
Follow-Up & Monitoring Schedule
Annual spirometry to track FEV1 decline. Assess inhaler technique and exacerbation frequency every 3-6 months.
Preventive Strategies
Never starting smoking. Occupational dust/chemical hazard avoidance.
Incurable but manageable. BODE index (BMI, Obstruction, Dyspnea, Exercise capacity) predicts 4-year survival.